Pfizer
NEWS
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
The pharma industry began to push back against the presidential blueprint for drug prices ahead of the election. Will that continue with a now divided Congress?
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
While many consider failure to be a completely negative experience, that’s not always the case, as every failure is still a lesson learned. Occasionally, these failures can even lead to some of the biggest breakthroughs in medical history.
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
The U.S. FDA approved Pfizer’s Lorbrena (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients whose disease hasn’t progressed on crizotinib and at least one other ALK inhibitor or for patients whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor.
Biopharma companies make key appointments to fill leadership positions. Let’s take a look!
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the company’s chief executive officer.
JOBS
IN THE PRESS